Company news
Shanghai MicuRx Pharmaceutical Co., Ltd. news in 2026
Shanghai MicuRx Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2026, newest first.
(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction
November 3, 2026
(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Report for Q3 2026
October 28, 2026
(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 31st Meeting of the 2nd Board of Directors
October 28, 2026
(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Signing of Authorization and License Agreement with ClearideBio
October 9, 2026
(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors
October 9, 2026
Announcement on Progress of Litigation Involving a U.S. Subsidiary
September 24, 2026
Announcement on Shareholding Reduction Plan of Shareholder
September 22, 2026
Announcement on Expiration of Shareholding Reduction Plan by Shareholder and Results of Shareholding Reduction
September 9, 2026
Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 4, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 25, 2026
Announcement on Continued Use of Idle Raised Funds for Cash Management
July 27, 2026
Announcement on Resignation of Securities Affairs Representative
July 7, 2026
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
June 22, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 2, 2026
Announcement on Shareholding Reduction Plan for Shareholders
May 18, 2026
Notice on Convening the 2025 Annual General Meeting
May 12, 2026
Announcement on Expiration of Shareholding Reduction Plan of Shareholder and Results of Shareholding Reduction
May 6, 2026
Announcement on Expiration of Shareholding Reduction Plan of Shareholder and Results of Shareholding Reduction and Change in Equity Reaching 1% Scale
April 30, 2026
Announcement on Resolutions of the 27th Meeting of the 2nd Board of Directors
April 28, 2026
Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
April 24, 2026
Announcement on Postponing Some Investment Projects Financed by Raised Funds
March 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 27, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
February 10, 2026
Announcement on Voluntary Disclosure of Permission Granted by the US for the Initiation of Clinical Trials of MRX-5
January 28, 2026
Earnings Preannouncement for 2025
January 23, 2026
Announcement on Voluntary Disclosure of the Company Certified as a High-tech Enterprise
January 14, 2026
Announcement on Change of Securities Affairs Representative
January 13, 2026
Announcement on Voluntary Disclosure of Compensation for the Patent Protection Period of the Company's Core Products
January 8, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
January 7, 2026
Announcement on Resignation of Directors and Senior Management Members
December 31, 2025